Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways

被引：35
|
作者：
Li, Qianbin [1 ]
Wu, Jingde [1 ]
Zheng, Hui [2 ]
Liu, Kai [1 ]
Guo, Tai L. [3 ]
Liu, Yuying [2 ]
Eblen, Scott T. [2 ]
Grant, Steven [4 ]
Zhang, Shijun [1 ]
机构：
[1] Virginia Commonwealth Univ, Dept Med Chem, Sch Pharm, Richmond, VA 23298 USA
[2] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA
[3] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
[4] Virginia Commonwealth Univ, Dept Internal Med & Biochem, Richmond, VA 23298 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 15期
关键词：
Dual pathway inhibitor; Raf/MEK/ERK; PI3K/Akt; Thiazolidine-2,4-dione; PROTEIN-KINASE PATHWAY; HUMAN LEUKEMIA-CELLS; PROSTATE-CANCER; MOUSE MODEL; INVOLVEMENT; APOPTOSIS; 3-KINASE; GROWTH; RAS;
D O I：
10.1016/j.bmcl.2010.06.030
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A thiazolidine-2,4-dione derivative, 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione (2), was identified as a dual inhibitor of the Raf/MEK/ extracellular signal-regulated kinase (ERK) and the phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascades. The discovered compound inhibited cell proliferation, induced early apoptosis, and arrested cells in G(0)/G(1) phase in human leukemia U937 cells. These results indicate its potential as a new lead compound to develop novel dual signaling pathway inhibitors and anticancer agents. Published by Elsevier Ltd.
引用
收藏
页码：4526 / 4530
页数：5
相关论文
共 50 条
  • [1] 3-(2-Diisopropylaminoethyl)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione
    Holota, Serhii
    Yushyn, Ihor
    Gzella, Andrzej
    Lesyk, Roman
    MOLBANK, 2022, 2022 (03)
  • [2] Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling
    Jung, Kwan-Young
    Samadani, Ramin
    Chauhan, Jay
    Nevels, Kerrick
    Yap, Jeremy L.
    Zhang, Jun
    Worlikar, Shilpa
    Lanning, Maryanna E.
    Chen, Lijia
    Ensey, Mary
    Shukla, Sagar
    Salmo, Rosene
    Heinzl, Geoffrey
    Gordon, Caryn
    Dukes, Troy
    MacKerell, Alexander D., Jr.
    Shapiro, Paul
    Fletcher, Steven
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2013, 11 (22) : 3706 - 3732
  • [3] Biological Characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a Selective Sphingosine Kinase-2 Inhibitor and Anticancer Agent
    Liu, Kai
    Guo, Tai L.
    Hait, Nitai C.
    Allegood, Jeremy
    Parikh, Hardik I.
    Xu, Wenfang
    Kellogg, Glen E.
    Grant, Steven
    Spiegel, Sarah
    Zhang, Shijun
    PLOS ONE, 2013, 8 (02):
  • [4] 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway
    Shi, Yanan
    Qiao, Jiayun
    Mu, Biao
    Zuo, Bingfeng
    Yuan, Jihong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 493 (01) : 286 - 290
  • [5] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
    Qingfang Li
    Zhihui Li
    Ting Luo
    Huashan Shi
    Molecular Biomedicine, 3
  • [6] Role of the Raf/MEK/ERK and the PI3K/Akt(PKB) pathways in fibroblast senescence
    Lorenzini, A
    Tresini, M
    Mawal-Dewan, M
    Frisoni, L
    Zhang, H
    Allen, RG
    Sell, C
    Cristofalo, VJ
    EXPERIMENTAL GERONTOLOGY, 2002, 37 (10-11) : 1149 - 1156
  • [7] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
    Du, Wei
    Pang, Changhe
    Xue, Yake
    Zhang, Qingjun
    Wei, Xinting
    ONCOLOGY LETTERS, 2015, 10 (05) : 3266 - 3270
  • [8] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
    Li, Qingfang
    Li, Zhihui
    Luo, Ting
    Shi, Huashan
    MOLECULAR BIOMEDICINE, 2022, 3 (01):
  • [9] Quantum chemical calculations and molecular docking studies of 5-(4-chlorobenzylidene)thiazolidine-2,4-dione(CTD) and its mannich product 5-(4-chlorobenzylidene)-3-(morpholinomethyl)thiazolidine-2,4-dione (CMTD)
    Fatma, Shaheen
    Bishnoi, Abha
    Verma, Anil Kumar
    Singh, Vineeta
    Srivastava, Krishna
    JOURNAL OF MOLECULAR STRUCTURE, 2018, 1157 : 177 - 190
  • [10] Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Saini, Kamal S.
    Loi, Sherene
    de Azambuja, Evandro
    Metzger-Filho, Otto
    Saini, Monika Lamba
    Ignatiadis, Michail
    Dancey, Janet E.
    Piccart-Gebhart, Martine J.
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 935 - 946
12345